AMENDMENTS TO THE CLAIMS

The listing of claims below will replace all prior versions and listing of claims in the above-identified application. Deleted matter is indicated by strikethrough or double brackets, and added matter is indicated by underlining.

1-13 (Cancelled)

14. (Currently amended) A propellant free buccal spray composition for transmucosal administration of a pharmacologically active compound soluble in a pharmacologically acceptable polar solvent comprising a polar solvent in an amount ranging from 37-98.58% and an active compound in an amount ranging from 0.005-55% by weight of the total composition;

wherein the active compound ~~comprises~~ is selected from the group consisting of a central nervous system active amine, a sulfonyl urea, an antibiotic, an antifungal, an antiviral, a sleep inducer, an antiasthmatic, an antiemetic, a histamine H-2 receptor antagonist, a barbiturate, a prostaglandin or a bronchial dilator ~~comprising terbutaline or theophyline~~; and

wherein the buccal spray composition is capable of providing transmucosal absorption of the active compound through the oral mucosa of a mammal to the systemic circulatory system of the mammal.

15. (Previously presented) The composition of claim 14, further comprising a flavoring agent in an amount ranging from 0.1 to 10 percent by weight of the composition.

16. (Previously presented) The composition of claim 15, wherein the polar solvent is present in an amount ranging from 60.0 to 90.06 percent by weight of the composition, the active compound is present in an amount ranging from 0.01 to 40 percent by weight of the composition, and the flavoring agent is present in an amount ranging from 0.75 to 7.5 percent by weight of the composition.

17. (Previously presented) The composition of claim 14, wherein the polar solvent comprises a low molecular weight polyethylene glycol (PEG) having a molecular weight ranging from 400 to 1,000, a C_2 to C_8 mono- and polyalcohol, or an alcohol of C_7 to C_{18} hydrocarbon of linear or branched configuration.

18. (Previously presented) The composition of claim 14, wherein the solvent comprises aqueous polyethylene alcohol.

19. (Previously presented) The composition of claim 14, wherein the solvent comprises aqueous ethanol.

20. (Currently amended) The composition of claim 14, wherein the active compound ~~comprises~~ is selected from the group consisting of cyclosporine, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost, thromethamine or valerian in its non-ionized form or a pharmaceutically acceptable sale thereof.

21. (Previously presented) A method of administering a pharmacologically active compound to a mammal in need thereof, comprising spraying the oral mucosa of the mammal with the composition of claim 14.

22. (Previously presented) The method of claim 21, wherein the amount of the spray is predetermined.

23. (New) A method for administering an effective amount of a pharmacologically active compound to a mammal to provide transmucosal absorption of a pharmacologically effective amount of the active compound through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising:

spraying the oral mucosa of the mammal with a propellant free buccal spray composition, containing a pharmacologically active compound dissolved in a pharmacologically acceptable solvent, comprising in weight percent of the composition:

a polar solvent in an amount ranging from 37-98.58%; and

an active compound in an amount ranging from 0.005-55% by weight of the total composition; wherein the active compound is selected from the group consisting of a central nervous system active amine, a sulfonyl urea, an antibiotic, an antifungal, an antiviral, a sleep inducer, an antiasthmatic, an antiemetic, a histamine H-2 receptor antagonist, a barbiturate, a prostaglandin or a bronchial dilator.

24. (New) The method of claim 23, further comprising a flavoring agent in an amount ranging from 0.1 to 10 percent by weight of the composition.

25. (New) The method of claim 24, wherein the polar solvent is present in an amount ranging from 60.0 to 90.06 percent by weight of the composition, the active compound is present in an amount ranging from 0.01 to 40 percent by weight of the composition, and the flavoring agent is present in an amount ranging from 0.75 to 7.5 percent by weight of the composition.

26. (New) The method of claim 23, wherein the polar solvent comprises a low molecular weight polyethylene glycol (PEG) having a molecular weight ranging

from 400 to 1,000, a C_2 to C_8 mono- and polyalcohol, or an alcohol of C_7 to C_{18} hydrocarbon of linear or branched configuration.

27. (New) The method of claim 23, wherein the solvent comprises aqueous polyethylene alcohol.

28. (New) The method of claim 23, wherein the solvent comprises aqueous ethanol.

29. (New) The method of claim 23, wherein the active compound is selected from the group consisting of cyclosporine, clozapine, zidevudine, erythromycin, ondansetron, cimetidine, phenytoin, carboprost, thromethamine or valerian in its non-ionized form or a pharmaceutically acceptable salt thereof.